Trials that use: Log-rank test
New to this method? Read the tutorial →
368 results
- Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer: Complete Statistical AnalysisIndependent statistical analysis of Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00920816).
- Azacitidine and Pembrolizumab in Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Azacitidine and Pembrolizumab in Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03264404).
- Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome: primary endpoint…
- AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02513563).
- BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Be Fit in Residency: a Randomized Controlled Trial of an Activity Device Among Medicine Residents: Complete Statistical AnalysisIndependent statistical analysis of Be Fit in Residency: a Randomized Controlled Trial of an Activity Device Among Medicine Residents: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- BELLE-2Independent statistical analysis of the BELLE-2 phase 3 trial of BKM120 plus fulvestrant versus placebo plus fulvestrant in postmenopausal patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer refractory to…
- BELLE-4Independent statistical analysis of A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation: primary endpoint results,…
- BETonMACEComplete statistical analysis of the BETonMACE phase 3 trial of apabetalone versus placebo in high-risk patients with type 2 diabetes and coronary artery disease, including time-to-event methodology, hazard ratios, confidence intervals, p-values,…
- Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma: Complete Statistical AnalysisIndependent statistical analysis of Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1): Complete Statistical AnalysisIndependent statistical analysis of BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1): primary endpoint results, effect estimate with confidence interval,…
- Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Bosutinib in Adult Patients With Recurrent Glioblastoma: Complete Statistical AnalysisIndependent statistical analysis of Bosutinib in Adult Patients With Recurrent Glioblastoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01331291).
- BREAKWATERIndependent statistical analysis of the BREAKWATER phase 3 trial of encorafenib plus cetuximab with or without chemotherapy in previously untreated metastatic colorectal cancer, including trial design, primary endpoints, hazard ratios, odds ratios,…
- BRIGHT AML1019Independent statistical analysis of A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia: primary endpoint results, effect estimate…
- BTX-A-HAC NGIndependent statistical analysis of Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients: Complete Statistical AnalysisIndependent statistical analysis of Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00879996).
- Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC): Complete Statistical AnalysisIndependent statistical analysis of Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04631744).
- Cannabidiol and Management of Endometriosis Pain: Complete Statistical AnalysisIndependent statistical analysis of Cannabidiol and Management of Endometriosis Pain: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04527003).
- CANTATAIndependent statistical analysis of CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- CANTOSAn independent statistical analysis of the phase 3 CANTOS trial (NCT01327846), comparing three canakinumab doses with placebo for first adjudicated major adverse cardiovascular events in 10066 participants with atherosclerosis, with hazard ratios,…
- Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction: Complete Statistical AnalysisIndependent statistical analysis of Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction: primary endpoint results, effect estimate with confidence…
- Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00514540).
- Carboxyamidotriazole in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Carboxyamidotriazole in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- CASPIANIndependent statistical analysis of CASPIAN, the randomized phase 3 trial of durvalumab with platinum-based chemotherapy in untreated extensive-stage small cell lung cancer, including overall survival, progression-free survival, response, statistical methodology, and interpretation.
- CASSIOPEIAA complete statistical analysis of the phase 3 CASSIOPEIA trial evaluating daratumumab in transplant-eligible participants with previously untreated multiple myeloma, including trial design, primary endpoints, reported statistical analyses, safety, and interpretation.
- CC-5013 (Lenalidomide) and Rituximab in Waldenstrom’s Macroglobulinemia: Complete Statistical AnalysisIndependent statistical analysis of CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00142168).
- CCRC: A Project of the Treatment of HIV Enteropathy With ImmunoLin® Supplements: Complete Statistical AnalysisIndependent statistical analysis of CCRC: A Project of the Treatment of HIV Enteropathy With ImmunoLin® Supplements: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- CELESTIALIndependent statistical analysis of the phase 3 CELESTIAL trial of cabozantinib versus placebo in hepatocellular carcinoma after prior sorafenib, including overall survival, progression-free survival, objective response, trial design, and statistical methodology.
- Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Cetuximab and Lenalidomide in Head and Neck: Complete Statistical AnalysisIndependent statistical analysis of Cetuximab and Lenalidomide in Head and Neck: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01133665).
- Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Cetuximab Plus Conformal Thoracic Radiotherapy in Patients (Pts) With Inoperable or Unresectable Locally Advanced Non-Small Cell Lung Cancer (LA – NSCLC): Complete Statistical AnalysisIndependent statistical analysis of Cetuximab Plus Conformal Thoracic Radiotherapy in Patients (Pts) With Inoperable or Unresectable Locally Advanced Non-Small Cell Lung Cancer (LA - NSCLC): primary endpoint results, effect estimate with confidence…
- CHAARTEDIndependent statistical analysis of CHAARTED (NCT00309985), a randomized phase 3 trial of androgen-deprivation therapy with or without docetaxel in metastatic hormone-sensitive prostate cancer.
- CHALLENGEIndependent statistical analysis of Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer: primary endpoint results, effect estimate…
- CheckMate 8HWIndependent statistical analysis of A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC):…
- CheckMate 914Independent statistical analysis of A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney: primary endpoint…
- CheckMate-017Independent statistical analysis of CheckMate-017, the randomized phase 3 trial of nivolumab versus docetaxel in previously treated advanced or metastatic squamous cell non-small cell lung cancer, including its overall-survival analysis and statistical…
- CheckMate-026Independent statistical analysis of CheckMate-026, a randomized phase 3 trial of nivolumab versus investigator's choice chemotherapy as first-line therapy for stage IV or recurrent PD-L1+ non-small cell lung cancer.
- CheckMate-141Independent statistical analysis of CheckMate-141, the randomized phase 3 trial of nivolumab versus investigator's choice therapy in recurrent or metastatic squamous cell carcinoma of the head and neck.
- CheckMate-816Independent statistical analysis of CheckMate-816, a randomized phase 3 trial of nivolumab plus platinum-doublet chemotherapy versus chemotherapy alone in early-stage non-small cell lung cancer.
- CheckMate901A detailed statistical analysis of CheckMate901, a randomized phase 3 trial evaluating nivolumab, ipilimumab, and standard chemotherapy in untreated inoperable or metastatic urothelial cancer.
- Chemoradiation and Tetrathiomolybdate (TM) in Patients With Esophageal Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Chemoradiation and Tetrathiomolybdate (TM) in Patients With Esophageal Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00176800).
- Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers: Complete Statistical AnalysisIndependent statistical analysis of Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Cinnamon Extract on Menstrual Cycles in PolyCystic Ovary Syndrome (PCOS): Complete Statistical AnalysisIndependent statistical analysis of Cinnamon Extract on Menstrual Cycles in PolyCystic Ovary Syndrome (PCOS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01483118).
- CIRTIndependent statistical analysis of Cardiovascular Inflammation Reduction Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01594333).
- Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- CLEAR OutcomesIndependent statistical analysis of CLEAR Outcomes, the randomized phase 3 trial of bempedoic acid versus placebo in statin-intolerant participants with or at high risk for cardiovascular disease, including MACE, secondary time-to-event endpoints,…